HLA alleles are associated with altered risk for disease progression and central nervous system impairment of HIV-infected children

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 1, 2011, Pages 32-39

  Singh, Kumud K ^a   Gray, Ping Kathryn ^b,c   Wang, Yan ^b   Fenton, Terence ^b   Trout, Rodney N ^a   Spector, Stephen A ^a,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

children; CNS impairment; HIV 1 related disease; HLA alleles

Indexed keywords

DIDANOSINE; HLA B27 ANTIGEN; HLA DQB1 ANTIGEN; ZIDOVUDINE;

ALLELE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; DISEASE COURSE; FEMALE; FOLLOW UP; GENOTYPE; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT;

ADOLESCENT; ALLELES; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; POLYMERASE CHAIN REACTION;

EID: 79955025414     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182119244     Document Type: Article

References (37)

1. Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases. Clin Microbiol Rev. 2009;22:370-385.
2. Aguado B, Bahram S, Beck S, et al. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature. 1999;401:921-923.
3. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med. 2000; 343:702-709.
4. Gandhi RT, Walker BD. Immunologic control of HIV-1. Annu Rev Med. 2002;53:149-172. (Pubitemid 34177876)
5. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature. 2001;410:980-987. (Pubitemid 32335849)
6. Norris PJ, Rosenberg ES. CD4(+) T helper cells and the role they play in viral control. J Mol Med. 2002;80:397-405. (Pubitemid 34754205)
7. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med. 2003;54:535-551. (Pubitemid 37386411)
8. Klein J, Sato A. The HLA system. Second of two parts. N Engl J Med. 2000;343:782-786.
9. Schneidewind A, Brockman MA, Sidney J, et al. Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. J Virol. 2008;82:5594-5605. (Pubitemid 351705266)
10. Kaslow R, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med. 1996;2:405-411. (Pubitemid 26193012)
11. McNeil A, Yap P, Gore S, et al. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. Q J Med. 1996; 89:177-185. (Pubitemid 26086136)
12. Magierowska M, Theodorou I, Debré P, et al. Combined genotypes of CCR5, CCR2, SDF1 and HLA genes can predict the long-term non-progressor status in HIV-1-Infected individuals. Blood. 1999;93:936-941. (Pubitemid 29067859)
13. Easterbrook P. Long-term non-progression in HIV infection: definitions and epidemiological issues. J Infect. 1999;38:71-73. (Pubitemid 29229629)
14. Mathieu A, Paladini F, Vacca A, et al. The interplay between the geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis. Autoimmun Rev. 2009;8: 420-425.
15. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA. 2000;97: 2709-2714. (Pubitemid 30159236)
16. Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med. 1997;336: 1704-1712.
17. McKinney RE Jr, Johnson GM, Stanley K, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr. 1998; 133:500-508. (Pubitemid 28465375)
18. Singh KK, Spector SA. Fidelity of whole-genome amplification of blood spot DNA for HLA typing and SNP analyses. Clin Genet. 2007;72:156-159. (Pubitemid 47262087)
19. Prentice L. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986;73:1-11.
20. Chen K, Lo S-H. Case-cohort and case-control analysis with Cox's model. Biometrika. 1999;86:755-764.
21. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics. 1994;50:1064-1072.
22. Therneau TM, Grambsch PM. Modeling Survival Data. New York, NY: Springer; 2000.
23. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999; 283:1748-1752.
24. Doherty PC, Zinkernagel RM. Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex. Nature. 1975;256:50-52.
25. Zinkernagel RM. Immunology taught by viruses. Science. 1996;271:173-178. (Pubitemid 26033295)
26. Gao X, O'Brien TR, Welzel TM, et al. HLA-B alleles associate consistently with HIV heterosexual transmission, viral load, and progression to AIDS, but not susceptibility to infection. AIDS. 2010; 24:1835-1840.
27. Salgado M, Simón A, Sanz-Minguela B, et al. An additive effect of protective host genetic factors correlates with HIV-non progression status. J Acquir Immune Defic Syndr. 2011;56:300-305.
28. Klein MR, van der Burg SH, Hovenkamp E, et al. Characterization of HLAB57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J Gen Virol. 1998;79: 2191-2201. (Pubitemid 28423414)
29. Goulder PJ, Bunce M, Krausa P, et al. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses. 1996;12:1691-1698. (Pubitemid 26424047)
30. Gillespie GM, Kaul R, Dong T, et al. Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B-57. AIDS. 2002;16:961-972. (Pubitemid 34499419)
31. Schneidewind A, Tang Y, Brockman MA, et al. Maternal transmission of human immunodeficiency virus escape mutations subverts HLA-B57 immunodominance but facilitates viral control in the haploidentical infant. J Virol. 2009;83:8616-8627.
32. Boulet S, Song R, Kamya P, et al. HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J Immunol. 2010;184:2057-2064.
33. Dean M, Carrington M, O'Brien SJ. Balanced polymorphism selected by genetic versus infectious human disease. Ann Rev Genomics Hum Genet. 2002;3:263-292. (Pubitemid 35217438)
34. Singh KK, Barroga CF, Hughes MD, et al. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. J Infect Dis. 2003;188:1461-1472. (Pubitemid 37523931)
35. Singh KK, Hughes MD, Chen J, et al. Lack of protective effects of interleukin-4 -589-C/T polymorphism against HIV-1-related disease progression and central nervous system impairment, in children. J Infect Dis. 2004;189:587-592. (Pubitemid 38270910)
36. Singh KK, Hughes MD, Chen J, et al. Impact of MCP-1-2518-G allele on the HIV-1 disease of children in the United States. AIDS. 2006;20: 475-478.
37. Hardie RA, Luo M, Bruneau B, et al. Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS. 2008;22:807-816. (Pubitemid 351563829)